Despite significant effort, patients with kidney disease have not seen their outcomes improved significantly over the past two decades. This has motivated clinicians and researchers to consider alternative methods to identifying risk factors, disease progression markers, and effective therapies. Genome-scale data sets from patients with renal disease can be used to establish a platform to improve understanding of the molecular basis of disease; however, such studies require expertise and resources. To overcome these challenges, we formed an academic–industry consortium to share molecular target identification efforts and expertise across academia and the pharmaceutical industry. The Renal Pre-Competitive Consortium (RPC²) aims to accelerate novel drug development for kidney diseases through a systems biology approach. Here, we describe the rationale, philosophy, establishment, and initial results of this strategy.

尽管付出了巨大的努力，但在过去的二十年中，肾病患者的预后并未得到明显改善。这激励了临床医生和研究人员考虑使用其他方法来识别危险因素，疾病进展标志物和有效疗法。来自肾脏疾病患者的基因组规模的数据集可用于建立一个平台，以增进对疾病分子基础的了解。但是，此类研究需要专业知识和资源。为了克服这些挑战，我们成立了一个学术行业联盟，以在整个学术界和制药行业分享分子靶标鉴定工作和专业知识。肾脏竞争前联合会（RPC ²）旨在通过系统生物学方法来加快针对肾脏疾病的新药开发。在这里，我们描述了该策略的原理，理念，建立和初步结果。